Filing Flows › Pacific Biosciences of California (PACB) › Q1 2026
Pacific Biosciences of California (PACB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
Pacific Biosciences of California (PACB) reported revenue of $37.2M for the first quarter 2026 (Q1 2026), +0.1% from a year earlier and -17% from the quarter before. Operating margin was -22.5%, net loss $8.3M (22.3% of revenue).
Pacific Biosciences of California, Q1 2026: revenue $37.2M (+0.1% year over year), operating margin -22.5%, net loss $8.3M, operating cash flow −$44.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.2M | -17% | +0.1% |
| Operating profit | −$8.4M | — | — |
| Net earnings | −$8.3M | — | — |
| Operating cash flow | −$44.7M | — | — |
What changed
Revenue was $37.2M in Q1 2026, roughly flat year over year and down 17% from the previous quarter. Consumable revenue was the largest line at 59% of revenue. Consumable revenue added $1.7M year over year (up 9%), 6864% of the total change. Instrument revenue declined 12%.
Gross margin was 34.5%. Operating costs exceeded revenue by $8.4M, an operating margin of -22.5%. The quarter ended with a net loss of $8.3M, narrower than the previous quarter's $40.4M loss.
Operating cash flow was −$44.7M. Non-cash charges added back $3.2M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $44.1M. Capital expenditures of $3.0M exceeded it, leaving free cash flow of −$47.7M.
Questions
What was Pacific Biosciences of California's revenue in the first quarter 2026?
Pacific Biosciences of California (PACB) reported revenue of $37.2M for the first quarter 2026 (Q1 2026), +0.1% from a year earlier and -17% from the quarter before.
Was Pacific Biosciences of California profitable in the first quarter 2026?
Operating loss was $8.4M (-22.5% of revenue) and net loss $8.3M.
Source: Pacific Biosciences of California 10-Q on SEC EDGAR.